Limited Edition Golden Llama is here! Check out how you can get one.
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free!
Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers !
Shipping Price Reduction for EU Regions
Kat. Nr. | Arten | Produktbeschreibung | Struktur | Reinheit | Merkmal |
---|---|---|---|---|---|
ILA-H5214 | Human | Human IL-1 alpha / IL-1F1 Protein, premium grade | ![]() |
![]() ![]() |
|
ILA-M82E8 | Mouse | Biotinylated Mouse IL-1 alpha / IL-1F1 Protein, His,Avitag™ (MALS verified) | ![]() |
![]() ![]() |
|
ILA-H82E7 | Human | Biotinylated Human IL-1 alpha / IL-1F1 Protein, His,Avitag™ (MALS verified) | ![]() |
![]() ![]() |
|
ILA-M5213 | Mouse | Mouse IL-1 alpha / IL-1F1 Protein, His Tag (MALS verified) | ![]() |
![]() ![]() |
|
ILA-H5216 | Human | Human IL-1 alpha / IL-1F1 Protein, His Tag (MALS verified) | ![]() |
![]() ![]() |
Human IL-1 RII, Fc Tag (Cat. No. IL2-H4256) immobilized on CM5 Chip can bind Human IL-1 alpha Protein, premium grade (Cat. No. ILA-H5214) with an affinity constant of 18.8 μM as determined in a SPR assay (Biacore 8K) (QC tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Rilonacept | RGN-303; KPL-914 | Approved | Arcalyst | United States | Cryopyrin-Associated Periodic Syndromes | Kiniksa Pharmaceuticals Ltd | 2008-02-27 | Pericarditis; Inflammation; Scleroderma, Diffuse; Renal Insufficiency, Chronic; Gout; Urticaria; Cryopyrin-Associated Periodic Syndromes; Hearing Loss, Sensorineural; Genetic Diseases, Inborn; Diabetes Mellitus, Type 1; Arthritis, Juvenile; Deficiency of interleukin-1 receptor antagonist; Scleroderma, Systemic; Muckle-Wells Syndrome (MWS); Anemia; Schnitzler Syndrome; Familial Mediterranean Fever; Still's Disease, Adult-Onset | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Tadekinig alfa (AB2 Bio) | Phase 3 Clinical | Ab2 Bio Ltd | Macrophage Activation Syndrome; Cytokine Release Syndrome; Lymphohistiocytosis, Hemophagocytic | Details | |
Bermekimab | T2-18C3; RA-18C3; CV-18C3; CA-18C3; MABP-1; MABp1; JNJ-77474462; MAB-p1 | Phase 2 Clinical | Xbiotech Inc | Acne Vulgaris; Hematologic Neoplasms; Pyoderma Gangrenosum; Digestive System Diseases; Diabetes Mellitus, Type 2; Neoplasms; Scleroderma, Systemic; Psoriasis; Colorectal Neoplasms; Hidradenitis Suppurativa; Eczema; Dermatitis, Atopic | Details |
lutikizumab | ABT-981 | Phase 2 Clinical | Abbvie Inc | Osteoarthritis, Knee; Colitis, Ulcerative; Hidradenitis Suppurativa; Osteoarthritis | Details |
AC-701 | AC-701 | Phase 2 Clinical | Twi Pharmaceuticals Inc | Rosacea; Exanthema | Details |
Vilamakitug | XB-2001 | Phase 2 Clinical | Xbiotech Inc | Pancreatic Neoplasms; Arthritis, Rheumatoid; Rheumatic Diseases | Details |
CAN-10 | CAN-10 | Phase 1 Clinical | Lund University Foundation | Scleroderma, Systemic; Psoriasis; Myocarditis; Plaque psoriasis | Details |
Hutrukin | Phase 1 Clinical | Xbiotech Inc | Details |
This web search service is supported by Google Inc.